linjc16/ctgov huggingface dataset:
Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate, whether the FeNO concentration of asthmatic children is influenced differently by inhaled corticosteroid compared to inhaled corticosteroid + long acting beta agonist. The study hypothesis is that the FeNO concentration is more decreased in patients with a combination therapy compared to those with a corticosteroid mono therapy.

Conditions
-----------------
Allergic Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: allergic asthma since > 6 months equal or lower corticosteroid therapy before study entry FEV1>50% Exclusion Criteria: severe asthma respiratory infection within the last 4 weeks smoking

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Appropriate Laryngeal Mask Airway Size in Patients With Overweight: A Comparison of the Actual Body Weight and Ideal Body Weight

Study Overview
=================
Brief Summary
-----------------
The classic laryngeal mask airway is one of the keystones of modern anaesthetic practice. It achieves a reliable airway with a low incidence of major complications and pharynges-laryngeal morbidity. The manufactures of laryngeal mask airway recommend the proper size selection by actual body weight. It was recommended a size 3 for 30-70kg, a size 4 for 70-90 kg, and size 5 for > 90 kg. Obesity increases the fat tissue around an upper airway and decreases the pharyngeal cross sectional area. Also it was reported that pharyngeal area was reduced according to the increasing of BMI. Therefore, the aim of this study is to determine which of actual body weight or ideal body weight is proper on the size selection of laryngeal mask airway.

Conditions
-----------------
General Anesthesia

Intervention / Treatment
-----------------
* Device: actual body weight based size
* Device: ideal body weight based size


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 20 70 body mass index > 25 kg/m2 patient who needs surgery with laryngeal mask airway Exclusion Criteria: difficult airway upper airway infection or disease of airway history of gastroesophageal reflux history of head and neck surgery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ideal body weight<br>LMA size based on ideal body weight | Device: ideal body weight based size<br>* According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.<br>|
| Experimental: actual body weight<br>LMA size according to actual body weight | Device: actual body weight based size<br>* According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oropharyngeal leak pressure | Oropharyngeal leak pressure is measured when the airway pressure becomes the plateau state in condition of gas flow 3 L/min and flow out valve 30 cmH2O. | 10mins | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
general anesthesia, body weight, laryngeal mask airway size
Minoxidil 2% for Eyebrow Enhancement

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to compare minoxidil 2% versus placebo in enhancement of eyebrows.

Official Title
-----------------
Efficacy and Tolerability of Minoxidil 2% for Eyebrow Enhancement : A Randomized , Double-blind , Placebo-controlled , Split-face Comparative Study

Conditions
-----------------
Hypotrichosis of Eyebrows, Thinning Eyebrows

Intervention / Treatment
-----------------
* Drug: Minoxidil lotion 2%
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male or female aged 18-40 years hypotrichosis of eyebrows healthy informed consent obtained Exclusion Criteria: no underlying diseases no alopecia areata or trichotillomania no thyroid diseases no pregnancy or breast feeding no previous eyebrow tattoo, trauma or accident. no history of eyebrow or hair medications in 6 months no history of minoxidil or its ingredient allergy no history of eyebrow surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Minoxidil lotion 2%<br>Minoxidil lotion 2% is applied twice daily to one eyebrow. | Drug: Minoxidil lotion 2%<br>* Minoxidil lotion 2% is applied twice daily to one eyebrow.<br>|
| Placebo Comparator: Placebo<br>Placebo is applied twice daily to the other eyebrow. | Drug: Placebo<br>* Placebo is applied twice daily to the other eyebrow.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change of global photographic assessment after 16 weeks from baseline |  | baseline and 16 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change of hair diameter after 16 weeks from baseline |  | baseline and 16 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypotrichosis of eyebrows, thinning eyebrows, minoxidil, placebo, randomized
Effectiveness of a Treatment Plan of Neurological Physiotherapy in Conjunction With Ultrasound-guided Ultrasound-guided Dry Needling in Stroke Patients.

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to assess the efficacy of dry needling in stroke patients in combination with intensive neurological physiotherapy. together with intensive neurological physiotherapy treatment. Randomised and blinded experimental study control group where the sample recruited was 20 patients, who were randomly assigned to a control group. randomly assigned to a control group, where they received intensive treatment, or to an intervention group, where they received intervention group, where they received ultrasound-guided dry needling of the tibialis anterior and posterior muscles followed by an intensive followed by intensive neurological physiotherapy treatment.

Official Title
-----------------
Effectiveness of a Treatment Plan of Neurological Physiotherapy in Conjunction With Ultrasound-guided Dry Needling in Stroke Patients.

Conditions
-----------------
Neurological Disorder

Intervention / Treatment
-----------------
* Device: dry needling
* Other: convencional treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: left middle cerebral artery infarction impaired stability during walking patient between the age range 18 to 70 years old Exclusion Criteria: patient under 18 years of age patients over 70 years of age undiagnosed left middle cerebral artery infarction patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: control group<br>conventional physiotherapy treatment | Other: convencional treatment<br>* is a physiotherapy treatment for neurological patients<br>|
| Experimental: dry needling treatment<br>group that includes a dry needling treatment on the tibialis anterior and posterior muscles. | Device: dry needling<br>* is a physiotherapy treatment for neurological patients and studies the efficacy of dry needling by studying several pre-treatment and post-treatment variables after the experimental treatment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| walking motor skills | measures of gait motor ability using the time up ang go test. | 1 hour | 
| spasticity | measurements of spatiality using the modified Ashworth scale | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dry needling, physiotherapy techniques, anterior tibial muscle, posterior tibial muscle, Neurological Disorder
Comparison Of The Berlin Questionnaire To The Portland Sleep Quiz

Study Overview
=================
Brief Summary
-----------------
This trial is enrolling patients who are already being seen at OHSU sleep disorder center or have been referred for clinical reasons by their physician to the OHSU sleep disorder center and are going to have a sleep study that would be paid for by their insurance company for clinical reasons. The purpose of this study is to determine whether the Portland sleep apnea quiz has a higher specificity and negative predictive value then the Berlin Sleep Questionnaire in a patient population with a high predisposition to sleep apnea presenting to a sleep center.

Detailed Description
-----------------
This trial is enrolling patients who are already being seen at OHSU sleep disorder center or have been referred for clinical reasons by their physician to the OHSU sleep disorder center and are going to have a sleep study that would be paid for by their insurance company for clinical reasons. 400 consecutive adult subjects who have been referred by their doctor to the sleep disorder center and are undergoing a diagnostic sleep study at the OHSU sleep disorders center will be requested to fill out both a Berlin questionnaire and Portland sleep quiz on the night of the initial diagnostic polysomnography. The questionnaires will be collected and scored in a confidential manner. The predictive value of the questionnaires will be compared with the results of overnight polysomnography (Apnea Hypopnea Index).

Official Title
-----------------
Comparison Of The Berlin Questionnaire To The Portland Sleep Quiz In Identification Of Patients At Risk For Obstructive Sleep Apnea

Conditions
-----------------
Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults more than 18 years old Exclusion Criteria: Subjects Unwilling to Complete the Questionnaire

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of 2 questionnaires |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obstructive Sleep Apnea
Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)

Study Overview
=================
Brief Summary
-----------------
Clozapine treatment resistant schizophrenia is still prevalent.The effectiveness of augmenting clozapine : one augmenting with haloperidol and the other with electroconvulsive therapy should be determined.This study is a randomized control trial.

Official Title
-----------------
Treatment of Clozapine-resistant Schizophrenia : Comparison Between Augmentation With Haloperidol and Electroconvulsive Therapy

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: clozapine+haloperidol
* Drug: clozapine,electroconvulsive therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: schizophrenic patients diagnosed with schedules for clinical assessment in neuropsychiatry ( SCAN )in accordance with DSM-IV-TR or ICD-10 Resistant to at least 6 weeks of clozapine treatment in therapeutic dosage Voluntary to participate the research protocol expressed by signing informed consent form Exclusion Criteria: Patient does not volunteer himself or herself Patient is having epilepsy, DM, cardiac disease, autistic disorder and illiterate Patient is deaf, blind , dumb to obstruct good communication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1.<br>clozapine as the main agent and it will be adjuncted by haloperidol | Drug: clozapine+haloperidol<br>* clozapine 300-900 mg/d haloperidol 4-60 mg/d<br>* Other names: clopaze, haloperidol;|
| Active Comparator: 2.<br>clozapine as the main agent and it will be adjuncted by electroconvulsive therapy | Drug: clozapine,electroconvulsive therapy<br>* clozapine 300-900 mg/d electroconvulsive therapy 4-12 times<br>* Other names: clopaze , Thymatron ECT machine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PANSS , HAM-D , CGI , AIMS Scores |  | every 4 weeks for 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
clozapine-resistant schizophrenics, haloperidol augmenting clozapine, electroconvulsive therapy augmenting clozapine
Serum Kisspeptin: a Predictive Marker of Miscarriage or Not?

Study Overview
=================
Brief Summary
-----------------
This is a prospective observational study. Eligible women undergo ART treatment in our centre will be recruited for the study and each woman will only be included in the study once. Informed written consent will be obtained. Blood serum for hCG level is performed 14 days after the embryo transfer i.e. week 4. If the serum hCG level is >10IU/L, the women are considered pregnant and blood will be saved and checked for kisspeptin level, Another blood test is repeated 1 week later i.e. week 5. A transvaginal ultrasound and blood test will be performed 1 week later i.e. week 6 to confirm the fetal viability and the number of gestational sacs and locate the pregnancy. Blood for hCG and kisspeptin levels are checked at weeks, 4, 5 and 6. Ultrasound will be performed at gestational 8 weeks and 11 weeks. They will be referred for antenatal care when the pregnancy is confirmed on-going at 11 weeks. The purpose is to determine whether serum kisspeptin level in women who conceive in IVF is associated with an increased risk in first trimester miscarriage and compare with serum hCG level in the prediction of the first trimester miscarriage.

Official Title
-----------------
A Prospective Study to Evaluate Whether Serum Kisspeptin is a Marker Predictive of the First Trimester Miscarriage of Women Who Conceive in IVF

Conditions
-----------------
Miscarriage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who have a positive pregnancy test following IVF or frozen-thawed transfer Exclusion Criteria: Women with renal failure are excluded due to assay interference with kisspeptin measurement
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early miscarriage loss | defined as intrauterine pregnancy loss at less than 10 weeks' gestation as identified by ultrasound, including identification of empty sac, miscarriage, yolk sac miscarriage and embryonic miscarriage | 10 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biochemical pregnancy | defined as pregnancy demise based on decreasing serum or urinary beta-HCG levels, without ultrasound visualization | 8 weeks | 
| Positive hCG level | conception is defined with the result of serum β-hCG ≥10 mIU/mL. | 4 weeks |
Early Endoscopic Indicators for OACs After Lung Transplantation: Development of a Novel Mucosal Healing Score

Study Overview
=================
Brief Summary
-----------------
Airway complications are a significant cause of morbidity after lung transplantation (LTx). Bronchoscopic evaluation may help to identify risk factors for requiring interventions later.

Detailed Description
-----------------
The investigators evaluated lung transplant recipients prospectively. Adult patients surviving 90 day after LTx will be included. The investigators propose a classification of airway healing based on the endoscopic bronchial appearances at days 7, 14, 21, 90, 180 and 365 after LTx. A score system including mucosal healing, full tissue necrosis (=dehiscence), lose sutures, fibrin plugs, polyps and malacia will be developed (max. score 8 points/date). Endoscopic findings will be correlated with the development of obstructive airway complications (OAC, requiring >1 intervention). Afterwards the new score system will be applied prospectively in the patients.

Official Title
-----------------
Early Indicators for Obstructive Airway Complications After Lung

Conditions
-----------------
Airway Complication Which Require Any Intervention

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 3 month survivor after LTx no OAC Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>patients with OAC, Score finding | |
| 2<br>patients without OAC, Score finding | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary endpoint of this study was any obstructive airway complication (AC) which required desobliterative intervention. |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| secondary endpoint included anastomosis-related death. |  | 1 year |
The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment

Study Overview
=================
Brief Summary
-----------------
HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses: Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.

Official Title
-----------------
The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment

Conditions
-----------------
HIV Positive, Opioid Dependence, Opioid Agonist Treatment, HIV Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV+ Opioid dependent Receiving methadone or buprenorphine for at least one month Exclusion Criteria: age < 18 years current dementia; inability to read or understand English inability to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HIV+, opiod dependent<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HIV drug resistance |  | Cross sectional | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Illicit drug use |  | 6 months | 
| HIV transmission risk behaviors |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, resistance, opioid dependence